Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects-Reference-Cited by-同舟云学术

Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects

Published:2017-01-04 Issue:371 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kublin James G.¹²³,Mikolajczak Sebastian A.¹,Sack Brandon K.¹,Fishbaugher Matt E.¹,Seilie Annette⁴,Shelton Lisa¹,VonGoedert Tracie¹,Firat Melike¹,Magee Sara¹,Fritzen Emma¹,Betz Will¹,Kain Heather S.¹,Dankwa Dorender A.¹,Steel Ryan W. J.¹,Vaughan Ashley M.¹,Noah Sather D.¹,Murphy Sean C.¹⁴⁵,Kappe Stefan H. I.¹²

Affiliation:

1. Center for Infectious Disease Research, formerly Seattle Biomedical Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA.

2. Department of Global Health, University of Washington, Seattle, WA 98195, USA.

3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109–1024, USA.

4. Department of Laboratory Medicine, University of Washington, 1959 Northeast Pacific Street, NW150, Seattle, WA 98195–7110, USA.

5. Center for Emerging and Re-emerging Infectious Diseases and Department of Microbiology, University of Washington, 750 Republican Street, E630, Seattle, WA 98109, USA.

Abstract

A genetically attenuated Plasmodium falciparum strain called Pf GAP3KO is completely attenuated, safe, and immunogenic in adults.

Funder

U.S. Army Medical Research

Bill and Melinda Gates Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference42 articles.

1. World Health Organization World Malaria Report 2015 (World Health Organization 2015).

2. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants